Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily (Q37680663)

21 August 2017

1 reference

title

Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily (English)

1 reference

21 August 2017

1 reference

1

Allan Flyvbjerg

1 reference

21 August 2017

publication date

1 February 2010

1 reference

Nature Reviews Endocrinology

21 August 2017

published in

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

94-101

1 reference

Pancreatic islet transplantation. Effects on the glomerular lesions of experimental diabetes in the rat.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The role of mannose-binding lectin in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

A second serine protease associated with mannan-binding lectin that activates complement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Characterization of the macrophage receptro for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Association between mannose-binding lectin and vascular complications in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Elevated levels of mannan-binding lectin in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Mannose-Binding Lectin and Mortality in Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Renal transplantation in diabetes mellitus in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Complement activation accelerates glomerular injury in diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Low serum C4 concentrations in type-1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Ultrastructural localization of the membrane attack complex of complement in human renal tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

31 March 2020

Trail and kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The death ligand TRAIL in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The MIF receptor CD74 in diabetic podocyte injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Prognostic value of apoptosis markers in advanced heart failure patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Assessment of a serum assay for quantification of abdominal aortic calcification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Increased Atherosclerotic Lesion Calcification in a Novel Mouse Model Combining Insulin Resistance, Hyperglycemia, and Hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Aortic collagen alterations in human diabetes mellitus. Changes in basement membrane collagen content and in the susceptibility of total collagen to cyanogen bromide solubilisation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Medial artery calcification predicts cardiovascular mortality in patients with NIDDM.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Osteoprotegerin and diabetic macroangiopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.266

Studies of the Rate of Regression of the Glomerular Lesions in Diabetic Rats Treated with Pancreatic Islet Transplantation

31 March 2020

1 reference

12 December 2020

Glomerular changes in mice with spontaneous hereditary diabetes.

1 reference

12 December 2020

Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women

1 reference

12 December 2020

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Low plasma C4 concentrations: association with microangiopathy in insulin dependent diabetes

1 reference

12 December 2020

Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention.

1 reference

12 December 2020

Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.266

1 reference

21 August 2017

1 reference